<SEC-DOCUMENT>0000078003-15-000046.txt : 20151023
<SEC-HEADER>0000078003-15-000046.hdr.sgml : 20151023
<ACCEPTANCE-DATETIME>20151023154624
ACCESSION NUMBER:		0000078003-15-000046
CONFORMED SUBMISSION TYPE:	SC 13G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20151023
DATE AS OF CHANGE:		20151023
GROUP MEMBERS:		C. P. PHARMACEUTICALS INTERNATIONAL C.V.
GROUP MEMBERS:		PFIZER MANUFACTURING LLC
GROUP MEMBERS:		PFIZER PRODUCTION LLC

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-50118
		FILM NUMBER:		151172902

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13G

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13G
<SEQUENCE>1
<FILENAME>2pro3g.htm
<DESCRIPTION>SCHEDULE 13G
<TEXT>

<head>
</head>

<p>&nbsp;</p>
<p align="center"><strong>UNITED STATES<br>
  SECURITIES AND EXCHANGE COMMISSION<br>
  WASHINGTON, D.C. 20549</strong> <br>
  <br>
  <strong>SCHEDULE 13G</strong> <br>
<strong>UNDER THE SECURITIES EXCHANGE ACT OF 1934<br>
    (Amendment No. )*</strong><br />
<br>
<strong>Protalix BioTherapeutics, Inc.</strong><br>
  (Name of Issuer)<br />
  <br>
  <strong>Common Stock, par value $0.001 per share  </strong><br>
  (Title of Class of Securities)<br>
  <br />
  <strong>74365A101</strong><br>
  (CUSIP Number)<br>
  <br>
  <strong>October 13, 2015</strong><br>
  (Date of Event Which Requires Filing of this Statement)</p>
<p align="left"><br>
  <br>
  Check the appropriate box to designate the rule pursuant to which this Schedule<br>
  is filed:<br>
  <br>
  |_| Rule 13d-1(b)<br>
  |X| Rule 13d-1(c)<br>
  |_| Rule 13d-1(d)<br>
  <br>
  *The remainder of this  cover page shall be filled out for a reporting  person's initial filing on this form with respect to the subject class of  securities, and for any subsequent amendment containing information which would  alter disclosures provided in a prior cover page.<br>
  <br>
  The information required  on the remainder of this cover page shall not be  deemed to be &quot;filed&quot; for the purpose of Section 18 of the Securities  Exchange  Act of 1934 (&quot;Act&quot;) or otherwise subject to the liabilities of that  section of  the Act but shall be subject to all other provisions of the Act (however, see  the Notes).</p>
<p align="left">CUSIP No.&nbsp;&nbsp;74365A101<br>
  --------------------------------------------------------------------------------<br>
  1) Names of Reporting  Persons. PFIZER INC.<br>
  I.R.S. Identification Nos. of Above Persons (entities only) 13-5315170<br>
  --------------------------------------------------------------------------------<br>
  2) Check the Appropriate  Box if a Member of a Group (See Instructions)<br>
  (a) |_|<br>
  (b) |X|<br>
  --------------------------------------------------------------------------------<br>
  3) SEC Use Only<br>
  --------------------------------------------------------------------------------<br>
  4) Citizenship or Place  of Organization<br>
  Delaware<br>
  --------------------------------------------------------------------------------</p>
<div align="left">
  <table border="0" cellpadding="0" width="88%">
    <tr>
      <td width="27%" rowspan="4">      NUMBER OF<br>
        SHARES <br>
        BENEFICIALLY <br>
        OWNED BY EACH    REPORTING<br>
        PERSON WITH: </td>
      <td width="73%"><p>5. Sole Voting Power    &nbsp;0</p></td>
    </tr>
    <tr>
      <td width="73%"><p>6. Shared Voting Power    &nbsp;5,649,079   shares of Common Stock, $0.001 par value per share (&quot;Common Stock&quot;)<kbd>(1)</kbd></p></td>
    </tr>
    <tr>
      <td width="73%"><p>7. Sole Dispositive    Power&nbsp;0</p></td>
    </tr>
    <tr>
      <td width="73%"><p>8. Shared Dispositive    Power 5,649,079  shares of Common Stock <kbd>(1)</kbd></p></td>
    </tr>
  </table>
</div>
<p>--------------------------------------------------------------------------------<br>
  9) Aggregate Amount  Beneficially Owned by Each Reporting Person 5,649,079  shares of Common Stock<kbd>(1)</kbd><br>
  10) Check if the  Aggregate Amount in Row (9) Excludes Certain Shares<br>
  (See Instructions) |_|<br>
  11) Percent of Class  Represented by Amount in Item 9 &nbsp;5.7%<kbd>(2)</kbd><br>
  12) Type of Reporting  Person (See Instructions)&nbsp;&nbsp; CO</p>
<p><br>
  </p>
<p align="left">CUSIP No.&nbsp;&nbsp;74365A101<br />
  --------------------------------------------------------------------------------<br />
  1) Names of Reporting  Persons. C. P. Pharmaceuticals International C.V. &nbsp;<br />
  I.R.S. Identification Nos. of Above Persons (entities only) 98-0182045<br />
  --------------------------------------------------------------------------------<br />
  2) Check the Appropriate  Box if a Member of a Group (See Instructions)<br />
  (a) |_|<br />
  (b) |X|<br />
  --------------------------------------------------------------------------------<br />
  3) SEC Use Only<br />
  --------------------------------------------------------------------------------<br />
  4) Citizenship or Place  of Organization<br />
  Netherlands<br />
  --------------------------------------------------------------------------------</p>
<div align="left">
  <table border="0" cellpadding="0" width="88%">
    <tr>
      <td width="27%" rowspan="4"> NUMBER OF<br />
        SHARES <br />
        BENEFICIALLY <br />
        OWNED BY EACH    REPORTING<br />
        PERSON WITH: </td>
      <td width="73%"><p>5. Sole Voting Power    &nbsp;0</p></td>
    </tr>
    <tr>
      <td width="73%"><p>6. Shared Voting Power    &nbsp;5,649,079   shares of Common Stock, $0.001 par value per share (&quot;Common Stock&quot;)<kbd>(1)</kbd></p></td>
    </tr>
    <tr>
      <td width="73%"><p>7. Sole Dispositive    Power&nbsp;0</p></td>
    </tr>
    <tr>
      <td width="73%"><p>8. Shared Dispositive    Power 5,649,079  shares of Common Stock<kbd>(1)</kbd></p></td>
    </tr>
  </table>
</div>
<p>--------------------------------------------------------------------------------<br />
  9) Aggregate Amount  Beneficially Owned by Each Reporting Person 5,649,079  shares of Common Stock<kbd>(1)</kbd><br />
  10) Check if the  Aggregate Amount in Row (9) Excludes Certain Shares<br />
  (See Instructions) |_|<br />
  11) Percent of Class  Represented by Amount in Item 9 &nbsp;5.7%<kbd>(2)</kbd><br />
  12) Type of Reporting  Person (See Instructions)&nbsp;&nbsp;PN<br />
  &nbsp;<br />
</p>
<p align="left">CUSIP No.&nbsp;&nbsp;74365A101<br>
  --------------------------------------------------------------------------------<br>
  1) Names of Reporting Persons. PFIZER PRODUCTION LLC<br>
  I.R.S. Identification Nos. of Above Persons (entities only) 52-2090275<br>
  --------------------------------------------------------------------------------<br>
  2) Check the Appropriate  Box if a Member of a Group (See Instructions)<br>
  (a) |_|<br>
  (b) |X|<br>
  --------------------------------------------------------------------------------<br>
  3) SEC Use Only<br>
  --------------------------------------------------------------------------------<br>
  4) Citizenship or Place  of Organization<br>
  Delaware<br>
  --------------------------------------------------------------------------------</p>
<div align="left">
  <table border="0" cellpadding="0" width="88%">
    <tr>
      <td width="27%" rowspan="4">      NUMBER OF<br>
        SHARES <br>
        BENEFICIALLY <br>
        OWNED BY EACH    REPORTING<br>
        PERSON WITH: </td>
      <td width="73%"><p>5. Sole Voting Power    &nbsp;0</p></td>
    </tr>
    <tr>
      <td width="73%"><p>6. Shared Voting Power    &nbsp;5,649,079   shares of Common Stock, $0.001 par value per share (&quot;Common Stock&quot;)<kbd>(1)</kbd></p></td>
    </tr>
    <tr>
      <td width="73%"><p>7. Sole Dispositive    Power&nbsp;0</p></td>
    </tr>
    <tr>
      <td width="73%"><p>8. Shared Dispositive    Power 5,649,079  shares of Common Stock <kbd>(1)</kbd></p></td>
    </tr>
  </table>
</div>
<p>--------------------------------------------------------------------------------<br>
  9) Aggregate Amount  Beneficially Owned by Each Reporting Person 5,649,079  shares of Common Stock<kbd>(1)</kbd><br>
  10) Check if the  Aggregate Amount in Row (9) Excludes Certain Shares<br>
  (See Instructions) |_|<br>
  11) Percent of Class  Represented by Amount in Item 9 &nbsp;5.7%<kbd>(2)</kbd><br>
  12) Type of Reporting Person (See Instructions)&nbsp;&nbsp; OO</p>
<p align="left">CUSIP No.&nbsp;&nbsp;74365A101<br>
  --------------------------------------------------------------------------------<br>
  1) Names of Reporting Persons. PFIZER MANUFACTURING LLC<br>
  I.R.S. Identification Nos. of Above Persons (entities only)&nbsp; 52-2090292<br>
  --------------------------------------------------------------------------------<br>
  2) Check the Appropriate  Box if a Member of a Group (See Instructions)<br>
  (a) |_|<br>
  (b) |X|<br>
  --------------------------------------------------------------------------------<br>
  3) SEC Use Only<br>
  --------------------------------------------------------------------------------<br>
  4) Citizenship or Place  of Organization<br>
  Delaware<br>
  --------------------------------------------------------------------------------</p>
<div align="left">
  <table border="0" cellpadding="0" width="88%">
    <tr>
      <td width="27%" rowspan="4">      NUMBER OF<br>
        SHARES <br>
        BENEFICIALLY <br>
        OWNED BY EACH    REPORTING<br>
        PERSON WITH: </td>
      <td width="73%"><p>5. Sole Voting Power    &nbsp;0</p></td>
    </tr>
    <tr>
      <td width="73%"><p>6. Shared Voting Power    &nbsp;5,649,079   shares of Common Stock, $0.001 par value per share (&quot;Common Stock&quot;)<kbd>(1)</kbd></p></td>
    </tr>
    <tr>
      <td width="73%"><p>7. Sole Dispositive    Power&nbsp;0</p></td>
    </tr>
    <tr>
      <td width="73%"><p>8. Shared Dispositive    Power 5,649,079  shares of Common Stock <kbd>(1)</kbd></p></td>
    </tr>
  </table>
</div>
<p>--------------------------------------------------------------------------------<br>
  9) Aggregate Amount  Beneficially Owned by Each Reporting Person 5,649,079  shares of Common Stock<kbd>(1)</kbd><br>
  10) Check if the  Aggregate Amount in Row (9) Excludes Certain Shares<br>
  (See Instructions) |_|<br>
  11) Percent of Class  Represented by Amount in Item 9 &nbsp;5.7%<kbd>(2)</kbd><br>
  12) Type of Reporting Person (See Instructions)&nbsp;&nbsp; OO<br>
  &nbsp;</p>
<p>ITEM 1.<br>
  (A) NAME OF ISSUER: Protalix BioTherapeutics, Inc.<br>
  (B) ADDRESS OF ISSUER'S  PRINCIPAL EXECUTIVE OFFICE:<br>
  2 Snunit Street, Science Park POB., Carmiel,  Israel 20100<br />
  <br>
  ITEM 2.<br>
  (A) NAME OF PERSONS  FILING:
This statement is being filed by Pfizer Inc., a Delaware corporation (&quot;Pfizer&quot;),
and Pfizer Production LLC, a Delaware limited liability company&nbsp; (&quot;PPL&quot;)
and &nbsp;Pfizer Manufacturing LLC, a Delaware limited liability company (&quot;PML&quot; and,
together with PPL, the &quot;General Partners&quot;), acting in their capacity as general
partners for and on behalf of&nbsp; C. P. Pharmaceuticals International C.V. , a
Netherlands limited partnership (collectively, the &quot;Shareholder&quot;). The
Shareholder and the General Partners are indirect wholly-owned subsidiaries of
Pfizer.&nbsp; <br>(B) ADDRESS OF PRINCIPAL  BUSINESS OFFICE OR IF NONE, RESIDENCE:<br />
&nbsp;The principal address of Pfizer, the Shareholder, PPL and PML is 235 E. 42nd Street,
New York, NY 10017. <br>(C) CITIZENSHIP: Pfizer, PPL and PML are Delaware and
the Shareholder is the Netherlands <br>
  (D) TITLE OF CLASS OF  SECURITIES: COMMON STOCK<br>
  (E) CUSIP NUMBER: &nbsp;74365A101 <br>
  ITEM 3. <br>
  Not applicable. <br>
  ITEM 4. OWNERSHIP.<br>
  (a) Amount beneficially  owned: 5,649,079   shares of Common Stock<kbd>(1)</kbd> <br>
  (b) Percent of class: 5.7% <kbd>(2)</kbd><br>
  (c) Number of shares as  to which the person has: <br>
  (i) Sole power to vote  or to direct the vote: &nbsp;0<br>
  (ii) Shared power to  vote or to direct the vote: 5,649,079  shares of Common Stock<kbd>(1)</kbd> <br>
  (iii) Sole power to  dispose or to direct the disposition of: &nbsp;0<br>
(iv) Shared power to  dispose or to direct the disposition of:&nbsp;&nbsp;&nbsp;5,649,079  shares of Common Stock<kbd>(1)</kbd></p>
<p><kbd>(1)</kbd> Amount consists of 5,649,079  shares of the Issuer's Common Stock held by
the Shareholder. &nbsp;Pfizer  may be deemed to have beneficial ownership over such shares since
the Shareholder is an indirect wholly-owned subsidiary of Pfizer.&nbsp; The
General Partners may be
deemed to have beneficial ownership over such shares as the general partners of
the Shareholder.&nbsp; </p>
<p><kbd>(2)</kbd>The ownership percentage of the Reporting Person  has been calculated on the basis of
99,774,270 shares of Common Stock   outstanding as provided to
the Reporting Persons by the Issuer (including the shares of Common Stock issued
to the Reporting Person).</p>
<p>ITEM 5. OWNERSHIP OF  FIVE PERCENT OR LESS OF A CLASS<br>
  Not applicable.<br>
  ITEM 6. OWNERSHIP OF  MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON<br>
  Not applicable.<br>
  ITEM 7.  &nbsp;IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE  SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY<br>
  Not applicable.<br>
  ITEM 8. IDENTIFICATION  AND CLASSIFICATION OF MEMBERS OF THE GROUP<br>
  Not applicable.<br>
  ITEM 9. NOTICE OF  DISSOLUTION OF GROUP<br>
  Not applicable.<br>
  ITEM 10. CERTIFICATION.<br>
  <br>
  By signing below I  certify that, to the best of my knowledge and belief, the  securities referred to above were not acquired and are not held for the purpose  of or with the effect of changing or influencing the control of the issuer of  the securities and were not acquired and are not held in connection with or as  a  participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &sect;240.14a-11.</p>
<p align="center"><br>
  &nbsp;<strong>Signature</strong></p>
<p>  After reasonable inquiry and to the best of my knowledge and belief, I certify  that the information set forth in this statement is true, complete and correct.<br>
  <br>
  Dated: October  23, 2015<br>
  <br />
  <strong>PFIZER INC.</strong><br>
  <br>
  By: /s/ Susan Grant<br>
  Name: Susan Grant<br>
  Title: Assistant Secretary</p>
<p><strong>For and on behalf of C. P. PHARMACEUTICALS INTERNATIONAL C.V. , </strong>by its General Partners </p>
<p>Pfizer Production LLC <br>as general partner for and on behalf of C. P.
Pharmaceuticals International C.V. <br />
By: /s/ Colum Lane<br />
Name:&nbsp; Colum Lane<br />
Title: Senior Vice President </p>
<p>Pfizer Manufacturing LLC<br>as general partner for and on behalf of C. P.
Pharmaceuticals International C.V.&nbsp; <br />
By: /s/ Brian McMahon<br />
Name: Brian McMahon<br />
Title: Senior Vice President </p>
<p align="left">
  <strong>PFIZER PRODUCTION LLC</strong><br>
  <br>
  By: /s/ Darren Welsh<br>
  Name: Darren Welsh<br>
  Title: Secretary</p>
<p align="left"><strong>PFIZER MANUFACTURING LLC</strong><br>
  <br>
  By: /s/ Darren Welsh<br>
  Name: Darren Welsh<br>
  Title: Secretary</p>
<p align="left">&nbsp;</p>
<p align="left">&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nex1pro.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>

<HTML><HEAD>
<TITLE>Exhibit</TITLE>
</HEAD>
<BODY>
<P align=right>
<div align="right"><strong>Exhibit 99.1</strong></div>
<FONT face="Courier New"
size=3></FONT>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p align="center"><strong>Joint Filing Agreement Pursuant to Rule 13d-1</strong> </p>
<p align="left"><br>
  This agreement is  made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934,  as amended (the &ldquo;Act&rdquo;) by and among the parties listed below, each referenced  to herein as a &ldquo;Joint Filer.&rdquo; The Joint Filers agree that a statement of  beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the  Rules thereunder may be filed on each of their behalf on Schedule 13G or  Schedule 13D, as appropriate, and that said joint filing may thereafter be  amended by further joint filings. The Joint Filers state that they each satisfy  the requirements for making a joint filing under Rule 13d-1.</p>
<p align="left"><br>
Dated: October  23, 2015</p>
<p align="left"><br>
  <strong>PFIZER INC.</strong><br>
  <br>
  By: /s/ Susan Grant<br>
  Name: Susan Grant<br>
  Title: Assistant Secretary</p>
<p align="left"><br>
  <strong>For and on behalf of&nbsp; C. P. PHARMACEUTICALS INTERNATIONAL C.V., </strong>by its General  Partners <br>
  Pfizer Production LLC <br>as general partner for and on behalf of C. P.
Pharmaceuticals International C.V. <br>
  By: /s/ Colum Lane<br>
  Name: Colum Lane<br>
  Title: Senior Vice President <br>
  <br>
  Pfizer Manufacturing LLC <br>as general partner for and on behalf of C. P.
Pharmaceuticals International C.V. <br>
  By: /s/ Brian McMahon<br>
  Name: Brian McMahon<br>
  Title: Senior Vice President </p>
<p align="left">
  <strong>PFIZER PRODUCTION LLC</strong><br>
  <br>
  By: /s/&nbsp; Darren Welsh<br>
  Name: Darren Welsh<br>
  Title: Secretary</p>
<p align="left"><strong>PFIZER MANUFACTURING LLC</strong><br>
  <br>
  By: /s/&nbsp; Darren Welsh<br>
  Name: Darren Welsh<br>
  Title: Secretary</p>
<p align="left">&nbsp;</p>
<p align="left">&nbsp;</p>
<p align="left">&nbsp;</p>
<p align="left">&nbsp;</p>
</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
